{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-054630","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-11-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.857293+00:00","generated_at":"2026-06-07T21:29:38.869395+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Roivant subsidiary Priovant's Phase 2 lupus study of oral brepocitinib fails primary endpoint","bullets":["Oral brepocitinib did not meet primary endpoint of SRI-4 at Week 52 in moderate-to-severe active lupus.","Highest placebo response rate observed in any significant SLE study prevented differentiation; active arm showed high SRI-4 rates.","Priovant will not progress brepocitinib in SLE but continues in non-infectious uveitis and dermatomyositis.","Topline results for NIU Phase 2 expected Q1 2024; dermatomyositis Phase 3 topline in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-054630","json":"https://secwatch.observer/filing/0001140361-23-054630.json","markdown":"https://secwatch.observer/filing/0001140361-23-054630.md","text":"https://secwatch.observer/filing/0001140361-23-054630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123054630/0001140361-23-054630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123054630/ef20015420_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:29:38.869395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}